Fosun Pharma starts pediatric brain cancer drug trial

Shanghai Fosun Pharmaceutical Group initiated a Phase III clinical trial of Ruimaining for pediatric low-grade glioma in China. The company has invested RMB 607 million in R&D for the drug, which already has two approved indications.

Fosun Pharma provided RMB 650 million in guarantees to subsidiaries Fosun Pharma Industrial and Henlius Biotech, bringing total outstanding guarantees to approximately RMB 2.44 billion within its RMB 3.5 billion approved limit.

The company repaid RMB 410 million in raised funds previously used for temporary working capital.